TNDM TANDEM DIABETES CARE INC

Nasdaq tandemdiabetes.com


$ 15.16 $ 0.00 (0 %)    

Friday, 07-Nov-2025 08:12:32 EST
QQQ $ 608.94 $ 0.00 (0 %)
DIA $ 468.45 $ 0.00 (0 %)
SPY $ 668.34 $ 0.00 (0 %)
TLT $ 89.46 $ 0.00 (0 %)
GLD $ 367.69 $ 0.00 (0 %)
$ 13.33
$ 14.61
$ 15.47 x 52
$ 15.74 x 33
-- - --
$ 9.98 - $ 38.28
2,814,966
na
903.81M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 04-30-2025 03-31-2025 10-Q
4 02-26-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-21-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-22-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 02-24-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 07-30-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-24-2020 12-31-2019 10-K
25 11-04-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 04-30-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 07-30-2018 06-30-2018 10-Q
31 04-26-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 10-26-2017 09-30-2017 10-Q
34 07-27-2017 06-30-2017 10-Q
35 04-27-2017 03-31-2017 10-Q
36 03-08-2017 12-31-2016 10-K
37 11-01-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 04-28-2016 03-31-2016 10-Q
40 02-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tandem-diabetes-care-affirms-fy2025-sales-guidance-of-1000b-vs-998025m-est

Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2025 sales outlook from $1.000 billion to $1.000 billion vs $998.025 million estim...

 tandem-diabetes-care-q3-adj-eps-031-inline-sales-249253m-beat-236963m-estimate

Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. Thi...

 tandem-diabetes-care-achieves-isoiec-270012022-certification-from-insight-assurance

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achie...

 tandem-diabetes-care-announces-that-its-tslim-x2-insulin-pump-with-control-iq-automated-insulin-delivery-now-integrates-with-abbotts-freestyle-libre-3-plus-cgm-in-the-us

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim ...

 dexcom-faces-new-reports-of-deaths-linked-to-g7-glucose-monitor

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

 stifel-reinstates-hold-on-tandem-diabetes-care-announces-15-price-target

Stifel analyst Jonathan Block reinstates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and announces $15 price target.

 truist-securities-maintains-hold-on-tandem-diabetes-care-raises-price-target-to-16

Truist Securities analyst Richard Newitter maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises the price tar...

 citigroup-maintains-neutral-on-tandem-diabetes-care-raises-price-target-to-15

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target fro...

 canaccord-genuity-maintains-buy-on-tandem-diabetes-care-maintains-24-price-target

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ: TNDM) with a Buy and maintains $24 price ...

 tandem-diabetes-cares-tslim-x2-insulin-pump-with-control-iq-aid-technology-cleared-for-use-with-eli-lillys-lyumjev-ultra-rapid-acting-insulin-in-us

Tandem Diabetes Care, Inc.

 tandem-diabetes-study-finds-automated-insulin-delivery-benefits-adults-with-type-2-diabetes-regardless-of-c-peptide-levels-challenging-current-cms-coverage-criteria

This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and...

 jim-cramer-this-is-the-right-time-to-buy-this-energy-stock

Mad Money's Jim Cramer looks at Phillips 66 and Intuitive Surgical, as well as Tandem Diabetes Care and Cintas.

 oppenheimer-maintains-outperform-on-tandem-diabetes-care-lowers-price-target-to-22

Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price targ...

 citigroup-upgrades-tandem-diabetes-care-to-neutral-raises-price-target-to-1035

Citigroup analyst Joanne Wuensch upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Sell to Neutral and raises the price targe...

 barclays-maintains-overweight-on-tandem-diabetes-care-lowers-price-target-to-51

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION